Effect of nicotinamide riboside supplementation in dilated cardiomyopathy patients

Chromadex Inc. USA0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年5月1日

试验速览

暂无简介。

•1.Meeting criteria for dilated cardiomyopathy (DCM) :
•a.Left ventricular ejection fraction <45%
•b.Left ventricular enlargement (A left ventricular end-diastolic dimension > 112% predicted value corrected for age and body surface area).
•c.Having conventional risk factors for DCM, including obesity, routinely treated hypertension, alcohol use, pregnancy or the peripartum period, or left ventricular noncompaction.
•2.Any age (including children)
•3.Ability to give informed consent

•1.Coronary artery disease (CAD) causing ischemic cardiomyopathy ( > 50% narrowing, any major epicardial coronary artery)
•2.Primary valvular disease
•3.Adriamycin or other cardiotoxic drug exposure
•4.Other forms of cardiomyopathy: Hypertrophic, Restrictive, or Arrhythmogenic Right
•5.Ventricular Dysplasia/Cardiomyopathy
•6.Congenital heart disease
•7.Other detectable causes of dilated cardiomyopathy, including sarcoid and hemochromatosis.
•8.Other active multi-system disease that may cause DCM (e.g., active connective tissue disease).
•9.Severe and untreated or untreatable hypertension
•10.Absence of systemic hypertension( >160/100 mm Hg)
•11.Pericardial diseases
•12.Cor pulmonale

发起方

Chromadex Inc. USA